Neurodevelopmental outcomes of preterm infants fed high-dose docosahexaenoic acid: a randomized controlled trial
Makrides M, Gibson RA, McPhee AJ, Collins CT, Davis PG, Doyle LW, Simmer K, Colditz PB, Morris S, Smithers LG, Willson K, Ryan P
JAMA · 253 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2009-01-13 · JAMA · vol. 301 · número 2 · pág. 175
- Editorial
- American Medical Association
- Citado
- 380 citas · más que el 100% de estudios similares · 28.4× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 32 trabajos
- Acceso
- De pago
- Áreas de investigación
- Fatty Acid Research and Health · Infant Nutrition and Health · Infant Development and Preterm Care
- Palabras clave
- docosahexaenoic acid, preterm infants, brain development, enteral nutrition, DHA supplementation, cognitive development, Bayley Scales of Infant Development, sex differences, birth weight, very low birth weight infants, omega-3 fatty acids, infant formula supplementation, gestational age, corrected age, term-equivalent age
- MeSH
- humans, docosahexaenoic acids, double-blind method, child development, neuropsychological tests, dietary supplements, infant, infant, newborn, infant, premature, female, male
12 autores
- Maria Makrides🇦🇺 · autor de correspondenciaWomen's and Children's Hospital; Women's & Children's Health Research Institute; Women's and Children's Health Network
- Robert Alan Gibson
- Andrew J McPhee
- Carmel T Collins
- Peter Graham Davis🇦🇺The University of Melbourne
- Lex William Doyle🇦🇺The University of Melbourne
- Karen Norrie Simmer
- Paul B. Colditz🇦🇺The University of Queensland
- Scott Adam Morris
- Lisa Gaye Smithers
- Kristyn J. Willson🇦🇺The University of Adelaide
- Philip Ryan🇦🇺The University of Adelaide
Resumen
El texto original del estudio, en el idioma en que se publicó.
Context
Uncertainty exists about the benefit of dietary docosahexaenoic acid (DHA) on the neurodevelopment of preterm infants.
Objective
To determine the effect of meeting the estimated DHA requirement of preterm infants on neurodevelopment at 18 months' corrected age.
Design, setting, and participants
Randomized, double-blind controlled trial enrolling infants born at less than 33 weeks' gestation from April 2001 to October 2005 at 5 Australian tertiary hospitals, with follow-up to 18 months.
Intervention
High-DHA (approximately 1% total fatty acids) enteral feeds compared with standard DHA (approximately 0.3% total fatty acids) from day 2 to 4 of life until term corrected age.
Main outcome measures
Bayley Mental Development Index (MDI) at 18 months' corrected age. A priori subgroup analyses were conducted based on randomization strata (sex and birth weight or = 1250 g).
Results
Of the 657 infants enrolled, 93.5% completed the 18-month follow-up. Bayley MDI scores did not differ between the high- and standard-DHA groups (mean difference, 1.9; 95% confidence interval [CI], -1.0 to 4.7). The MDI among girls fed the high-DHA diet was higher than girls fed standard DHA in unadjusted and adjusted analyses (unadjusted mean difference, 4.7; 95% CI, 0.5-8.8; adjusted mean difference, 4.5; 95% CI, 0.5-8.5). The MDI among boys did not differ between groups. For infants born weighing less than 1250 g, the MDI in the high-DHA group was higher than with standard DHA in the unadjusted comparison (mean difference, 4.7; 95% CI, 0.2-9.2) but did not reach statistical significance following adjustment for gestational age, sex, maternal education, and birth order (mean difference, 3.8; 95% CI, -0.5 to 8.0). The MDI among infants born weighing at least 1250 g did not differ between groups.
Conclusion
A DHA dose of approximately 1% total fatty acids in early life did not increase MDI scores of preterm infants overall born earlier than 33 weeks but did improve the MDI scores of girls.
Trial registration
anzctr.org.au Identifier: ACTRN12606000327583.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.